代谢功能障碍相关脂肪性肝病合并丙型肝炎病毒感染患者的患病率与临床特征:一项基于人群的研究
该研究基于埃及国家病毒性肝炎控制委员会网络登记系统,纳入2007至2020年288,222例慢性HCV感染患者。41.9%(95%CI:41.69-42.05)符合MAFLD诊断标准,2014-2020年患病率较2007-2013年显著上升(43.3% vs 19%)。MAFLD患者肥胖、糖尿病、高血压患病率随时间显著增加,进展期纤维化比例亦显著升高。
要点
- 慢性HCV感染者中MAFLD患病率为41.9%(95%CI:41.69-42.05)。
- 2014-2020年MAFLD患病率43.3% vs 2007-2013年19%,呈显著上升。
- MAFLD患者肥胖、糖尿病、高血压患病率随年份显著增加。
核心结论
- MAFLD在HCV感染患者中患病率高且随时间上升,与肥胖、糖尿病和高血压的惊人上升平行。
- 建议对HCV感染患者早期检测代谢功能障碍以预防MAFLD进展。
研究设计与样本
- 基于埃及国家病毒性肝炎控制委员会网络登记系统的研究,纳入2007至2020年288,222例慢性HCV感染患者,收集人口学数据、实验室参数和超声检查。
主要发现
- 41.9%(95%CI:41.69-42.05)的参与者符合MAFLD诊断标准。
- 2014-2020年MAFLD患病率为43.3%,2007-2013年为19%。
- MAFLD患者中,2007-2013年与2014-2020年肥胖患病率分别为66.7% vs 76.9%(p < 0.01),糖尿病为14.6% vs 31.5%(p < 0.01),高血压为0.9% vs 7.6%(p < 0.01),糖尿病前期为28.8% vs 25.9%(p < 0.01)。
- MAFLD患者中,2014-2020年较2007-2013年FIB-4定义的进展期纤维化比例为18.4% vs 8%,NFS定义的进展期纤维化比例为17.1% vs 7%。
关键数值与推荐
- MAFLD诊断采用2020年提出的新诊断标准。
临床怎么用
- 作者建议对HCV感染患者早期检测代谢功能障碍以预防MAFLD进展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metabolic-associated fatty liver disease (MAFLD) was proposed in 2020 to identify fatty liver disease associated with metabolic risks. Metabolic abnormalities with hepatitis C virus (HCV) and MAFLD frequently co-exist. However, data on the co-existence are still lacking. AIM: To explore the prevalence and characteristics of metabolic profiles among a large cohort of patients with HCV infection between 2007 and 2020 based on new diagnostic criteria METHODS: We recruited 288,222 patients with chronic HCV infection with demographic data, laboratory parameters, and ultrasound from a web-based registry of the National Committee for Control of Viral Hepatitis in Egypt from 2007 to 2020. RESULTS: Among the participants, 41.9% (95% CI: 41.69-42.05) met diagnostic criteria for MAFLD, with a significant increase in the period 2014-2020 compared to 2007-2013 (43.3% vs. 19%, respectively). Participants with MAFLD had a high prevalence of obesity, diabetes mellitus and hypertension. The prevalences increased significantly over time (obesity: 66.7% vs. 76.9%, p < 0.01; diabetes mellitus: 14.6% vs. 31.5%, p < 0.01; hypertension: 0.9% vs. 7.6%, p < 0.01; prediabetes: 28.8% vs. 25.9%, p < 0.01) for the periods 2007-2013 and 2014-2020, respectively. The percentage of advanced fibrosis by fibrosis-4 index (FIB-4) and NAFLD fibrosis score (NFS) was significantly higher in participants with MAFLD during 2014-2020 than during 2007-2013 (FIB-4; 18.4% vs. 8% and NFS; 17.1% vs. 7%). CONCLUSION: MAFLD is highly prevalent in patients with HCV infection and has risen over time. This rising prevalence parallels the alarming rise in obesity, diabetes mellitus and hypertension. Early detection of metabolic dysfunction in patients with HCV infection is recommended to prevent MAFLD progression.
引用
- Attia D, Abdel Alem S, El-Akel W, et al. Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection-a population-based study. Aliment Pharmacol Ther. 2022. PMID: 36168675. doi:10.1111/apt.17233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。